Identification and Validation of PLOD2 As an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Dec 24

PMID 34944486

Citations 9

Authors

Yawei Sun

Shuai Wang

Xingwei Zhang

Zhuhao Wu

Zihui Li

Zhuang Ding

Xiaofeng Huang

Sheng Chen

Yue Jing

Xiaoxin Zhang

Liang Ding

Yuxian Song

Guowen Sun

Yanhong Ni

Affiliations

Soon will be listed here.

Abstract

Background: Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), a key enzyme that catalyzes the hydroxylation of lysine, plays a crucial role in the progression of several solid tumors. However, its spatial expression profile and prognostic significance in oral squamous cell carcinoma (OSCC) have not been revealed.

Materials: Mass spectrometry was used to explore amino acid perturbations between OSCC tumor tissues and paired normal tissues of 28 patients. Then, PLOD2 mRNA and protein levels were assessed using several public databases and 18 pairs of OSCC patients' tissues. Additionally, PLOD2 spatial expression profiles were investigated in 100 OSCC patients by immunohistochemistry and its diagnostic and prognostic values were also evaluated. Lastly, gene set enrichment analysis (GSEA) was used to investigate the potential functions of PLOD2 in OSCC.

Results: Lysine was significantly elevated in OSCC tissues and could effectively distinguish tumor from normal tissues (AUC = 0.859, = 0.0035). PLOD2 mRNA and protein levels were highly increased in tumor tissues of head and neck squamous cell carcinoma (HNSCC) ( < 0.001) and OSCC compared with those in nontumor tissues ( < 0.001). Histopathologically, PLOD2 was ubiquitously expressed in tumor cells (TCs) and fibroblast-like cells (FLCs) of OSCC patients but absent in tumor-infiltrating lymphocytes (TILs). Patients with highly expressed PLOD2 in TCs (PLOD2) and FLCs (PLOD2) showed poor differentiation, a worse pattern of invasion (WPOI) and more lymph node metastasis (LNM), contributing to higher postoperative metastasis risk and poor survival time. However, PLOD2 rather than PLOD2 was an independent risk factor for survival outcomes in OSCC patients. Molecularly, GSEA demonstrated highly expressed PLOD2 was mainly enriched in epithelial-mesenchymal transformation (EMT), TGF-beta signaling and hypoxia pathway, which are associated with poor clinical outcomes of OSCC patients.

Conclusions: PLOD2 was a poor prognostic biomarker for OSCC patients and may affect the metastasis of OSCC through EMT pathway. These findings might shed novel sights for future research in PLOD2 targeted OSCC therapy.

Citing Articles

Cellular and Molecular Effects of the Bruck Syndrome-Associated Mutation in the Gene.

Bolshakova O, Latypova E, Komissarov A, Slobodina A, Ryabova E, Varfolomeeva E Int J Mol Sci. 2025; 25(24.

PMID: 39769143 PMC: 11676324. DOI: 10.3390/ijms252413379.

Integrins as the pivotal regulators of cisplatin response in tumor cells.

Shad A, Moghbeli M Cell Commun Signal. 2024; 22(1):265.

PMID: 38741195 PMC: 11089694. DOI: 10.1186/s12964-024-01648-0.

[Advances of spatial omics in the individualized diagnosis and treatment of head and neck cancer].

Xu C, Wang Y, Wei D, Li W, Qian Y, Pan X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023; 37(9):729-733.

PMID: 37830120 PMC: 10722126. DOI: 10.13201/j.issn.2096-7993.2023.09.008.

Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells.

Xiong Y, Wang Y, Yang T, Luo Y, Xu S, Li L Am J Cardiovasc Drugs. 2023; 23(5):497-518.

PMID: 37524956 DOI: 10.1007/s40256-023-00596-3.

Prognostic model based on telomere-related genes predicts the risk of oral squamous cell carcinoma.

Yue K, Yao X BMC Oral Health. 2023; 23(1):484.

PMID: 37452322 PMC: 10347773. DOI: 10.1186/s12903-023-03157-x.

References

Bozoky B, Savchenko A, Csermely P, Korcsmaros T, Dul Z, Ponten F . Novel signatures of cancer-associated fibroblasts. Int J Cancer. 2013; 133(2):286-93. DOI: 10.1002/ijc.28035. View

Zhao M, Ding L, Yang Y, Chen S, Zhu N, Fu Y . Aberrant Expression Of PDCD4/eIF4A1 Signal Predicts Postoperative Recurrence For Early-Stage Oral Squamous Cell Carcinoma. Cancer Manag Res. 2019; 11:9553-9562. PMC: 6857661. DOI: 10.2147/CMAR.S223273. View

Yang X, Zhang X, Jing Y, Ding L, Fu Y, Wang S . Amino acids signatures of distance-related surgical margins of oral squamous cell carcinoma. EBioMedicine. 2019; 48:81-91. PMC: 6838421. DOI: 10.1016/j.ebiom.2019.10.005. View

Ueki Y, Saito K, Iioka H, Sakamoto I, Kanda Y, Sakaguchi M . PLOD2 Is Essential to Functional Activation of Integrin β1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas. iScience. 2020; 23(2):100850. PMC: 6997870. DOI: 10.1016/j.isci.2020.100850. View

Qi Y, Xu R . Roles of PLODs in Collagen Synthesis and Cancer Progression. Front Cell Dev Biol. 2018; 6:66. PMC: 6031748. DOI: 10.3389/fcell.2018.00066. View

Du W, Liu N, Zhang Y, Liu X, Yang Y, Chen W . PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2. Biochem Cell Biol. 2019; 98(3):386-395. DOI: 10.1139/bcb-2019-0256. View

Ding Z, He Y, Fu Y, Zhu N, Zhao M, Song Y . CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint. Front Oncol. 2021; 11:687430. PMC: 8239289. DOI: 10.3389/fonc.2021.687430. View

Saito T, Uzawa K, Terajima M, Shiiba M, Amelio A, Tanzawa H . Aberrant Collagen Cross-linking in Human Oral Squamous Cell Carcinoma. J Dent Res. 2019; 98(5):517-525. DOI: 10.1177/0022034519828710. View

Sada M, Ohuchida K, Horioka K, Okumura T, Moriyama T, Miyasaka Y . Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Cancer Lett. 2016; 372(2):210-8. DOI: 10.1016/j.canlet.2016.01.016. View

10.

Piersma B, Bank R . Collagen cross-linking mediated by lysyl hydroxylase 2: an enzymatic battlefield to combat fibrosis. Essays Biochem. 2019; 63(3):377-387. DOI: 10.1042/EBC20180051. View

11.

Liu J, Chen S, Wang W, Ning B, Chen F, Shen W . Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. Cancer Lett. 2016; 379(1):49-59. DOI: 10.1016/j.canlet.2016.05.022. View

12.

Han S, Huang T, Wu X, Wang X, Li W, Liu S . Prognostic value of ALDH1 and Nestin in advanced cancer: a systematic meta-analysis with trial sequential analysis. Ther Adv Med Oncol. 2019; 11:1758835919830831. PMC: 6393950. DOI: 10.1177/1758835919830831. View

13.

Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall J, Harrington K . Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007; 9(12):1392-400. DOI: 10.1038/ncb1658. View

14.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

15.

Kurozumi A, Kato M, Goto Y, Matsushita R, Nishikawa R, Okato A . Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol. 2016; 48(5):1837-46. PMC: 4809659. DOI: 10.3892/ijo.2016.3440. View

16.

Pankova D, Chen Y, Terajima M, Schliekelman M, Baird B, Fahrenholtz M . Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2015; 14(3):287-95. PMC: 4794404. DOI: 10.1158/1541-7786.MCR-15-0307. View

17.

Faubert B, Solmonson A, DeBerardinis R . Metabolic reprogramming and cancer progression. Science. 2020; 368(6487). PMC: 7227780. DOI: 10.1126/science.aaw5473. View

18.

Gilkes D, Bajpai S, Chaturvedi P, Wirtz D, Semenza G . Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem. 2013; 288(15):10819-29. PMC: 3624462. DOI: 10.1074/jbc.M112.442939. View

19.

Zhu N, Ding L, Fu Y, Yang Y, Chen S, Chen W . Tumor-infiltrating lymphocyte-derived MLL2 independently predicts disease-free survival for patients with early-stage oral squamous cell carcinoma. J Oral Pathol Med. 2019; 49(2):126-136. DOI: 10.1111/jop.12969. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View